Literature DB >> 23036570

Retinal nerve fiber layer atrophy is associated with visual field loss over time in glaucoma suspect and glaucomatous eyes.

Mitra Sehi1, Xinbo Zhang, David S Greenfield, Yunsuk Chung, Gadi Wollstein, Brian A Francis, Joel S Schuman, Rohit Varma, David Huang.   

Abstract

PURPOSE: To compare prospectively detection of progressive retinal nerve fiber layer thickness (RNFL) atrophy identified using time-domain optical coherence tomography with visual field progression using standard automated perimetry in glaucoma suspect and preperimetric glaucoma patients or perimetric glaucoma patients.
DESIGN: Prospective, longitudinal clinical trial.
METHODS: Eligible eyes with 2 years or more of follow-up underwent time-domain optical coherence tomography and standard automated perimetry every 6 months. The occurrence of visual field progression was defined as the first follow-up visit reaching a significant (P < .05) negative visual field index slope over time. RNFL progression or improvement was defined as a significant negative or positive slope over time, respectively. Specificity was defined as the number of eyes with neither progression nor improvement, divided by the number of eyes without progression. Cox proportional hazard ratios were calculated using univariate and multivariate models with RNFL loss as a time-dependent covariate.
RESULTS: Three hundred ten glaucoma suspect and preperimetric glaucoma eyes and 177 perimetric glaucoma eyes were included. Eighty-nine eyes showed visual field progression and 101 eyes showed RNFL progression. The average time to detect visual field progression in those 89 eyes was 35 ± 13 months, and the average time to detect RNFL progression in those 101 eyes was 36 ± 13 months. In multivariate Cox models, average and superior RNFL losses were associated with subsequent visual field index loss in the entire cohort (every 10-μm loss; hazard ratio, 1.38; P = .03; hazard ratio, 1.20; P = .01; respectively). Among the entire cohort of 487 eyes, 42 had significant visual field index improvement and 55 had significant RNFL improvement (specificity, 91.4% and 88.7%, respectively).
CONCLUSIONS: Structural progression is associated with functional progression in glaucoma suspect and glaucomatous eyes. Average and superior RNFL thickness may predict subsequent standard automated perimetry loss.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23036570      PMCID: PMC3525739          DOI: 10.1016/j.ajo.2012.07.005

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  44 in total

Review 1.  Functional assessment of glaucoma.

Authors:  P A Sample; C A Johnson
Journal:  J Glaucoma       Date:  2001-10       Impact factor: 2.503

2.  Retinal nerve fiber layer normative classification by optical coherence tomography for prediction of future visual field loss.

Authors:  Kyung Rim Sung; Sophia Kim; Youngrok Lee; Sung-Cheol Yun; Jung Hwa Na
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-22       Impact factor: 4.799

3.  Combining structural and functional measurements to improve estimates of rates of glaucomatous progression.

Authors:  Felipe A Medeiros; Linda M Zangwill; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb
Journal:  Am J Ophthalmol       Date:  2012-02-07       Impact factor: 5.258

4.  Quantifying discordance between structure and function measurements in the clinical assessment of glaucoma.

Authors:  Haogang Zhu; David P Crabb; Marie-Josée Fredette; Douglas R Anderson; David F Garway-Heath
Journal:  Arch Ophthalmol       Date:  2011-05-09

Review 5.  Optic nerve and retinal nerve fiber layer analyzers in glaucoma.

Authors:  David S Greenfield
Journal:  Curr Opin Ophthalmol       Date:  2002-04       Impact factor: 3.761

Review 6.  Assessment of rates of structural change in glaucoma using imaging technologies.

Authors:  K Mansouri; M T Leite; F A Medeiros; C K Leung; R N Weinreb
Journal:  Eye (Lond)       Date:  2011-01-07       Impact factor: 3.775

7.  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.

Authors:  Mae O Gordon; Julia A Beiser; James D Brandt; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Michael A Kass
Journal:  Arch Ophthalmol       Date:  2002-06

8.  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

Authors:  Michael A Kass; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John L Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson; Mae O Gordon
Journal:  Arch Ophthalmol       Date:  2002-06

9.  Evaluation of retinal nerve fiber layer progression in glaucoma a prospective analysis with neuroretinal rim and visual field progression.

Authors:  Christopher Kai Shun Leung; Shu Liu; Robert N Weinreb; Gilda Lai; Cong Ye; Carol Yim Lui Cheung; Chi Pui Pang; Kwok Kay Tse; Dennis Shun Chiu Lam
Journal:  Ophthalmology       Date:  2011-04-29       Impact factor: 12.079

10.  Evaluation of retinal nerve fiber layer progression in glaucoma: a comparison between spectral-domain and time-domain optical coherence tomography.

Authors:  Christopher Kai-Shun Leung; Vivian Chiu; Robert N Weinreb; Shu Liu; Cong Ye; Marco Yu; Carol Yim-Lui Cheung; Gilda Lai; Dennis Shun-Chiu Lam
Journal:  Ophthalmology       Date:  2011-04-29       Impact factor: 12.079

View more
  17 in total

Review 1.  Is There Any Role for the Choroid in Glaucoma?

Authors:  Iman Goharian; Mitra Sehi
Journal:  J Glaucoma       Date:  2016-05       Impact factor: 2.503

2.  Association of Structural and Functional Measures With Contrast Sensitivity in Glaucoma.

Authors:  Nima Fatehi; Sara Nowroozizadeh; Sharon Henry; Anne L Coleman; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Am J Ophthalmol       Date:  2017-03-23       Impact factor: 5.258

3.  Baseline factors predicting the risk of conversion from ocular hypertension to primary open-angle glaucoma during a 10-year follow-up.

Authors:  M L Salvetat; M Zeppieri; C Tosoni; P Brusini
Journal:  Eye (Lond)       Date:  2016-05-13       Impact factor: 3.775

Review 4.  Biomarkers and surrogate endpoints in glaucoma clinical trials.

Authors:  Felipe A Medeiros
Journal:  Br J Ophthalmol       Date:  2014-07-17       Impact factor: 4.638

5.  Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas.

Authors:  Sherry Gu; Natalie Glaug; Avital Cnaan; Roger J Packer; Robert A Avery
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-10       Impact factor: 4.799

6.  Corneal Hysteresis and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma.

Authors:  Chunwei Zhang; Andrew J Tatham; Ricardo Y Abe; Alberto Diniz-Filho; Linda M Zangwill; Robert N Weinreb; Felipe A Medeiros
Journal:  Am J Ophthalmol       Date:  2016-03-03       Impact factor: 5.258

7.  Relationship between corneal hysteresis and optic nerve parameters measured with spectral domain optical coherence tomography.

Authors:  Daniel M Vu; Fabiana Q Silva; Sarah J Haseltine; Joshua R Ehrlich; Nathan M Radcliffe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

8.  Rapid initial OCT RNFL thinning is predictive of faster visual field loss during extended follow-up in glaucoma.

Authors:  Swarup S Swaminathan; Alessandro A Jammal; Samuel I Berchuck; Felipe A Medeiros
Journal:  Am J Ophthalmol       Date:  2021-03-26       Impact factor: 5.488

Review 9.  Clinical Utility of Optical Coherence Tomography in Glaucoma.

Authors:  Zachary M Dong; Gadi Wollstein; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-07-01       Impact factor: 4.799

10.  Local Glaucomatous Defects of the Circumpapillary Retinal Nerve Fiber Layer Show a Variety of Patterns of Progression.

Authors:  Ha Min Kim; William E McKee; Katarzyna B Malendowicz; Abinaya A Thenappan; Emmanouil Tsamis; Melvi D Eguia; C Gustavo De Moraes; Robert Ritch; Donald C Hood
Journal:  J Glaucoma       Date:  2020-10       Impact factor: 2.290

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.